A
Aptevo Therapeutics Inc. (APVO)
NCM – Real Time Price. Currency in USD
4.83
-0.01 (-0.31%)
At close: May 12, 2026, 4:00 PM EDT
4.52
-0.31 (-6.42%)
Pre-market: May 13, 2026, 5:31 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
4.83
-0.01 (-0.31%)
At close: May 12, 2026, 4:00 PM EDT
4.52
-0.31 (-6.42%)
Pre-market: May 13, 2026, 5:31 AM EDT
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
| Name | Position |
|---|---|
| Dr. Dirk Huebner M.D. | Senior Vice President & Chief Medical Officer |
| Mr. Jeffrey G. Lamothe CA | CEO, President & Director |
| Mr. Marvin L. White | Executive Chair |
| Ms. Daphne L. Taylor CPA | Senior VP & CFO |
| Ms. Miriam Weber Miller | Vice President of Investor Relations & Corporate Communications |
| Ms. SoYoung Kwon J.D., LL.M. | Corporate Secretary, Senior VP, General Counsel, Business Development & Corporate Affairs |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 8-K | apvo-20260506.htm |
| 2026-03-26 | 8-K | apvo-20260326.htm |
| 2026-03-11 | 8-K | apvo-20260310.htm |
| 2026-02-19 | 8-K | apvo-20260218.htm |
| 2026-02-03 | 8-K | apvo-20260130.htm |
| 2026-01-28 | S-1 | apvo-20260128.htm |
| 2026-01-26 | DEF 14A | apvo-20260123.htm |
| 2026-01-16 | PRE 14A | apvo-20260116.htm |
| 2026-01-09 | 8-K | apvo-20260108.htm |
| 2025-12-29 | 8-K | apvo-20251229.htm |